Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
NHS Quality Improvement Scotland
Record ID 32005000708
English
Details
Project Status:
Completed
URL for project:
http://www.nhshealthquality.org/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland
MeSH Terms
- Aged
- Female
- Middle Aged
- Postmenopause
- Osteoporotic Fractures
- Diphosphonates
- Parathyroid Hormone
- Estrogen Receptor Modulators
- Alendronate
- Bone Density Conservation Agents
- Etidronic Acid
- Fractures, Cartilage
- Osteoporosis, Postmenopausal
- Raloxifene Hydrochloride
- Selective Estrogen Receptor Modulators
- Teriparatide
Contact
Organisation Name:
Quality Improvement Scotland
Contact Address:
Delta House, 50 West Nile Street Glasgow G1 2NP Scotland United Kingdom Tel: +44 141 225 6988; Fax: +44 141 221 3262
Contact Name:
shtg.hcis@nhs.net
Contact Email:
shtg.hcis@nhs.net
Copyright:
NHS Quality Improvement Scotland (NHS QIS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.